Since August 2025, Halozyme Therapeutics has been in a holding pattern, posting a small loss of 2.1% while floating around $70.71. The stock also fell short of the S&P 500’s 6.2% gain during that period.
Is now the time to buy HALO? Or does the price properly account for its business quality and fundamentals? Find out in our full research report, it’s free.
Why Does HALO Stock Spark Debate?
Known for transforming hours-long intravenous infusions into minutes-long subcutaneous injections, Halozyme Therapeutics (NASDAQ: HALO) develops and licenses its proprietary ENHANZE technology that enables subcutaneous delivery of injectable drugs that would otherwise require intravenous administration.
Two Things to Like:
1. Skyrocketing Revenue Shows Strong Momentum
Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Luckily, Halozyme Therapeutics’s sales grew at an incredible 39.2% compounded annual growth rate over the last five years. Its growth beat the average healthcare company and shows its offerings resonate with customers.
2. Outstanding Long-Term EPS Growth
We track the long-term change in earnings per share (EPS) because it highlights whether a company’s growth is profitable.
Halozyme Therapeutics’s EPS grew at an astounding 35.6% compounded annual growth rate over the last five years. This performance was better than most healthcare businesses.
One Reason to be Careful:
Free Cash Flow Margin Dropping
If you’ve followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can’t use accounting profits to pay the bills.
As you can see below, Halozyme Therapeutics’s margin dropped by 21.1 percentage points over the last five years. Continued declines could signal it is in the middle of an investment cycle. Halozyme Therapeutics’s free cash flow margin for the trailing 12 months was 46.2%.
Final Judgment
Halozyme Therapeutics has huge potential even though it has some open questions. With its shares trailing the market in recent months, the stock trades at 8.8× forward P/E (or $70.71 per share). Is now a good time to buy? See for yourself in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
